Section Arrow
Quote
ACTU.NASDAQ
- Actuate Therapeutics Inc
Quotes are at least 15-min delayed:2025/12/18 02:32 EST
Regular Hours
Last
 6.86
-0.1 (-1.44%)
Day High 
7.0301 
Prev. Close
6.96 
1-M High
7.9 
Volume 
29.35K 
Bid
6
Ask
8.2
Day Low
6.6499 
Open
6.92 
1-M Low
5.61 
Market Cap 
161.77M 
Currency 美元 
P/E 20.47 
%Yield -- 
10-SMA 7.34 
20-SMA 6.97 
50-SMA 6.93 
52-W High 11.99 
52-W Low 5.47 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.34/-0.97
Enterprise Value
161.77M
Balance Sheet
Book Value Per Share
0.47
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
VYNEVYNE Therapeutics0.6+0.1973+48.99%0.67PE
VTGNVistagen Therapeutics, Inc.0.861-3.499-80.25%-- 
RXRXRecursion Pharmaceuticals4.68+0.48+11.43%-- 
ADTXAditxt Inc1.74+0.32+22.54%0PE
PCSAProcessa Pharmaceuticals6.68+3.675+122.30%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.